Company intelligence / Profile preview

SciTech Development

Grosse Pointe Farms / Detroit area, Michigan, USAscitechdevelopment.com ↗

Ownership: Private
Development stage: Other

Overview

Preliminary Phase 1a data in CTCL shows successful targeted drug delivery, enhanced bioavailability, positive safety profile, and early clinical responses. The nanoparticle formulation enables rapid IV infusion of high-dose fenretinide while minimizing toxicity. FDA Orphan Drug Designation granted for NHL indications.

Therapeutic areas: Oncology
Modalities: Small molecules (fenretinide/nanoFenretinide)Nanoparticle drug delivery platform
Industry: Biotech

Drug pipeline

6 assets

fenretinide

5 more assets in the full pipeline.

Partnerships

National Cancer Institute – Provided fenretinide supply and supported development funding.Rush University Medical Center – Clinical trial site for ST‑001 nanoFenretinide in lymphoma.No major pharma partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on SciTech Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciTech Development.